What the Lawsuits Allege
These cases involve necrotizing enterocolitis, or NEC, a severe and sometimes fatal gastrointestinal disease in which intestinal tissue is damaged. Families allege that premature infants who were fed cow milk-based formula, primarily Abbott Similac and Mead Johnson Enfamil, in the NICU developed NEC, and that the manufacturers knew of a heightened NEC risk in preterm infants fed these formulas but failed to warn families and medical providers. The federal cases are consolidated as MDL 3026 in the Northern District of Illinois.
Abbott and Mead Johnson deny the claims and have raised defenses including federal preemption and the argument that no feasible safer alternative product existed. The scientific debate over the degree of risk, and whether these specific products caused a given child injury, is contested rather than settled.
The Verdicts and the State-Federal Split
The results so far have split sharply between state and federal courts, which is the most important thing to understand about any NEC payout question. In state courts, juries have returned large plaintiff verdicts, including a sixty million dollar Enfamil verdict, a substantial Similac verdict that drew national attention, and a later seventy million dollar verdict for several families. Like most large jury awards, these can be subject to post-trial reduction and appeal.
In the federal MDL, the picture has been different. The court granted summary judgment to Abbott in a series of early Similac bellwether cases, finding the plaintiffs had not shown a feasible alternative design, and a second wave of cases is now being worked up. So far there has been no federal MDL jury verdict and no approved global settlement.
What This Means for Case Value
Because there is no settlement fund and the courts have diverged, there is no standard NEC payout and no reliable average. The large state verdicts are individual results on specific facts, often involving a death or catastrophic bowel injury, and they do not predict what any other case is worth. The federal summary-judgment losses show that outcomes are far from guaranteed.
What tends to shape value in the cases that succeed is the severity of the outcome, such as death versus survivable injury, the medical evidence linking the formula to the NEC, the strength of the failure-to-warn case, and the venue. Eligibility generally centers on a premature infant who was fed a cow milk-based Similac or Enfamil product and received an NEC diagnosis, and deadlines apply, so an individual assessment is the right next step.
How to Get Legal Help
If you or a family member fits the description here, a consultation with a lawyer who handles this specific litigation is the reliable next step. Deadlines vary and can be unforgiving, most of these firms offer a free review, and these cases are typically taken on contingency, so you pay nothing unless they recover for you.
To follow filings, trial outcomes, and any settlement news, bookmark this page and subscribe to LawsuitWatch alerts.
Free Legal Evaluation
Do You Qualify to File a Claim?
Our network of verified plaintiff attorneys offers free, no-obligation case evaluations. Contingency fee representation means you pay nothing unless you win.
NEC Lawsuit Payout: What the Baby Formula Verdicts Actually Show: Frequently Asked Questions
Answers to the most common questions about this case and your legal options.
What is the average NEC lawsuit payout?
There is no reliable average and no settlement fund. The large state verdicts are individual results on specific facts, often involving a death or catastrophic injury, and the federal MDL has seen summary-judgment losses for plaintiffs, so outcomes are far from uniform.
What do the NEC lawsuits allege?
That premature infants fed cow milk-based formula, mainly Similac and Enfamil, in the NICU developed necrotizing enterocolitis, and that the makers knew of the heightened risk in preterm infants but failed to warn families and providers. The makers deny the claims.
Why have state and federal courts differed?
State juries have returned large plaintiff verdicts, while the federal MDL granted summary judgment to Abbott in several early Similac bellwethers over the lack of a feasible alternative design. There has been no federal MDL jury verdict yet.
What defenses do the formula makers raise?
They deny the claims and have raised defenses including federal preemption and the argument that no feasible safer alternative product existed. Whether the products caused a given child injury is contested.
Who may qualify and is there a deadline?
Eligibility generally centers on a premature infant fed a cow milk-based Similac or Enfamil product who received an NEC diagnosis. Deadlines apply and vary, so an individual legal assessment should not be delayed.